Valion Bio Announces Changes to Management and Board of DirectorsCurrent CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.
Valion Bio Announces Reverse Stock SplitSAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq").
Kartoon Studios (NYSE: TOON) Enters Next Growth Phase; Reports Q2 Revenue of $5.82M, EPS of $0.38 and $40.5M Cash Position – Plus More in FocusAug. 14, 2026 — Kartoon Studios, Inc. (
NYSE: TOON), a global children’s and family entertainment company, reported second-quarter 2026 financial results while outlining a strategic transformation centered on the ownership, development and commercialization of high-value intellectual property.
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment PhasePotential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government Procurement
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI InjuryAFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early Fall
